COVID-19 vaccine program


Second-generation candidate



First-generation candidate



prophylactic vaccines



CV7202 – Phase 1

CV7202 is a prophylactic mRNA-based vaccine encoding the rabies virus glycoprotein, RABV-G, formulated with next generation lipid nanoparticle (LNP).

CV7202 is currently being studied in a phase 1, dose-escalation, open-label clinical trial.

Study objectives:

  • Primary: Safety, reactogenicity
  • Secondary: Potential protective immune response, immunogenicity via geometric mean virus neutralization tests (VNT)

Rabies, a viral disease that causes inflammation in the brain, still occurs in more than 150 countries around the globe, with the infection responsible for more than 60,000 deaths every year, primarily in China and India.

More information about the CV7202 study can be found at (NCT03713086).

Lassa, yellow fever


Respirational syncytial virus

Other infectious diseases


CV7301 – Pre-clinical

CV7301 is a second-generation lipid nanoparticle (LNP) flu vaccine, which has demonstrated strong and durable immunogenicity in non-human primates.

Influenza is an annual global health concern, with the World Health Organization (WHO) estimating that influenza leads to approximately 290,000 to 650,000 deaths annually.

Various projects

Rota, malaria, universal influenza


Ongoing Research – Malaria & Rota – Research

With support from the Bill & Melinda Gates Foundation, research is being conducted to leverage CureVac’s prophylactic vaccine technology to develop mRNA-based vaccines to prevent infectious diseases that disproportionately affect people in the world’s poorest countries.


cancer immunotherapies


Cutaneous melanoma, adenoidcystic carcinoma, squamous cell cancer of skin, head and neck

CV8102 (Study 1) – Phase 1

CV8102, a TLR7/8/RIG-1 agonist based on noncoding single stranded RNA, is designed to modulate the tumor microenvironment after intratumoral injection and to induce a systemic immune response to control injected as well as non-injected distant lesions.

CV8102 is currently being studied in a Phase 1, open-label, dose escalation and expansion study, which is enrolling patients with advanced melanoma, cutaneous squamous cell carcinoma, squamous cell carcinoma of head and neck, or adenoidcystic carcinoma, and superficially injectable tumor lesions.

The trial is testing escalating doses of single agent CV8102 and CV8102 in combination with licensed anti-PD-1 antibodies.

Study objectives:

  • Primary: Safety, tolerability
  • Secondary: Clinical efficacy, changes in various immune parameters in blood and tumor tissue

More information about the CV8102 study can be found at

Tumor associated antigens (TAA)


Shared neo-antigens




Cas9 gene-editing


Gene-editing – Pre-clinical

CureVac is collaborating with CRISPR Therapeutics to develop novel Cas9 mRNA constructs, which have improved properties for gene editing applications, such as increased potency, decreased duration of expression, and reduced potential for immunogenicity.

For more information about our partnership with CRISPR click here.

Liver Diseases

Ocular diseases


Lung respiratory diseases


Therapeutic antibodies